Expanded Access to Provide SUVN-502 for the Treatment of Subjects With Alzheimer's Disease

An Intermediate-Size, Expanded Access to SUVN-502 for the Treatment of Subjects With Alzheimer's Disease Who Have Completed the CTP2S1502HT6 Study

Lead sponsor

Suven Life Sciences Limited

Asset

Masupirdine

Listed sites

Recruiting sites

Enrollment

Study population

Alzheimer’s disease

Key I/E criterion

•Age 50-85

Primary endpoint

Identifiers

Registered as

Org study IDEAP1502HT6

NCT IDNCT03564964

Timeline

Milestones

Study first posted2018-06-21actual

Last update posted2020-09-29actual

Assets

Drug assets

Masupirdine

Study populations

Who this study enrolls

Alzheimer’s disease

Eligibility

Who can enroll

Minimum age50 Years

Maximum age85 Years

SexAll

Inclusion criteria

•Subjects who have completed the 30 week treatment period of study CTP2S1502HT6 as planned and wish to continue treatment with SUVN-502.

•Subject (or subject's legally acceptable representative) and caregiver must sign the Informed Consent Form (ICF) to participate in the study

Exclusion criteria

•Has participated or is participating in any other clinical (investigational) study after completion of CTP2S1502HT6 study.

•Is treated or likely to require treatment during the study with any medication prohibited by this expanded access program.

Endpoints (0)

What's being measured

Protocol endpoints and posted registry outcome measures, grouped into outcome categories. Composite endpoints show their component event types. Standard codes (LOINC, SNOMED CT) are shown where available.

No endpoints recorded for this trial.

Provenance

Sources

Trial identity, design, statusClinicalTrials.gov API v2

Snapshot dateJuly 21, 2026

Endpoint classificationDelfa ADRD endpoint taxonomy

Results tableno registry results posted yet

Trial facts come from public ClinicalTrials.gov records. Endpoint categories are Delfa's classification of those records, not a ClinicalTrials.gov field. All figures reflect the July 21, 2026 snapshot.